Lin C et al. – This review summarized the existing literature and addressed a few key questions pertaining to the use of omalizumab with oral immunotherapy (OIT). Although OIT is an efficacious experimental approach to food allergy and provides substantial benefits with respect to allergen desensitization, it is associated with several limitations such as high rates of allergic reactions and limited and variable protection. Hence, several studies have evaluated omalizumab (anti–immunoglobulin E monoclonal antibody) as an adjuvant therapy for patients undergoing OIT. Results of these studies demonstrated that addition of omalizumab to OIT results in a significant increase in the threshold of tolerance to food allergens by significantly decreasing the frequency and severity of reactions.